Julien Rongère
General Counsel chez AC IMMUNE SA
Postes actifs de Julien Rongère
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| AC IMMUNE SA | General Counsel | 01/07/2017 | - |
Historique de carrière de Julien Rongère
Anciens postes connus de Julien Rongère
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Apoxis SA
 Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Corporate Officer/Principal | - | - |
Celgene Switzerland SARL
 Celgene Switzerland SARL Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Switzerland SARL is a Swiss biopharmaceutical company. The private company is based in Boudry, Switzerland. | General Counsel | - | - |
Formation de Julien Rongère
| University of Aberdeen | Graduate Degree |
| University of Lausanne | Doctorate Degree |
Statistiques
Internationale
| Suisse | 5 |
| Royaume-Uni | 2 |
Opérationnelle
| General Counsel | 2 |
| Graduate Degree | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Entreprise privées | 2 |
|---|---|
Apoxis SA
Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Health Technology |
Celgene Switzerland SARL
Celgene Switzerland SARL Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Switzerland SARL is a Swiss biopharmaceutical company. The private company is based in Boudry, Switzerland. | Health Technology |
- Bourse
- Insiders
- Julien Rongère
- Expérience
